MM-589 |
Catalog No.GC33278 |
MM-589 is a potent inhibitor of WD repeat domain 5 (WDR5) and mixed lineage leukemia (MLL) protein-protein interaction. MM-589 binds to WDR5 with an IC50 of 0.90 nM and inhibits the MLL H3K4 methyltransferase activity with an IC50 of 12.7 nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2097887-20-0
Sample solution is provided at 25 µL, 10mM.
MM-589 is a potent inhibitor of WD repeat domain 5 (WDR5) and mixed lineage leukemia (MLL) interaction. MM-589 binds to WDR5 with an IC50 of 0.90 nM and inhibits the MLL H3K4 methyltransferase activity with an IC50 of 12.7 nM[1].
MM-589 binds to WDR5 with high affinity (IC50=0.90 nM, Ki <1 nM) and potently inhibits the MLL HMT activity (IC50=12.7 nM)[1].MM-589 (0.01-10 µM, 4 days or 7 days) potently and selectively inhibits cell growth in human leukemia cell lines harboring MLL translocations[1].|| Cell Viability Assay[1]||Cell Line:|MV4-11 and MOLM-13|Concentration:|0.1, 1, 10 μM|Incubation Time:|4 days or 7 days|Result:|MM-589 potently inhibits MV4-11 and MOLM-13 cell growth with IC50s of 0.25 and 0.21 μM, respectively. MM-589 has much weaker activity in the inhibition of cell growth of the HL-60 cell line with an IC50 of 8.6 μM[1].
MM-589 has excellent microsomal stability in human, mouse, and rat microsomes (T1/2 > 60 min). Further optimization of MM-589 may yield a new therapy for acute leukemia[1].
[1]. Karatas H, et al. Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein Interaction. J Med Chem. 2017 Jun 22;60(12):4818-4839.
Average Rating: 5
(Based on Reviews and 40 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *